Genscript biotech shares associate’s Q3 2025 financial results

Genscript Biotech Corporation has issued a voluntary announcement regarding the financial performance of its associate, Legend Biotech Corporation, for the third quarter ended September 30, 2025. Legend, whose shares are listed as American Depository Shares on the Nasdaq Global Select Market, filed its Form 6-K with the United States Securities and Exchange Commission (SEC) on November 12, 2025.

The announcement highlights Legend's financial results and recent business developments, with detailed information accessible on the SEC's website. Genscript Biotech emphasizes that the reported financial results are solely for Legend and do not reflect the company's own performance.

Genscript Biotech advises shareholders and potential investors to exercise caution and assess investment risks when considering transactions involving the company's securities. The announcement, released from Hong Kong on November 12, 2025, was made by order of the board, with Robin Meng serving as chairman and executive director.